Systemic Lupus Erythematosus Clinical Trials in Houston, Texas

9 studies are recruiting for systemic lupus erythematosus in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

   This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are pu…

   Stage

   Phase 2

   Ages

   18 to 74

   Site

   The University of Texas Health Science Center at Houston, Houston, Texas

   Locations

   140 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07409181 on ClinicalTrials.gov

2. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT MD Anderson Cancer Center, Houston, Texas

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

3. An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

   A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Research Site, Houston, Texas

   Locations

   103 in total

   Run by

   AstraZeneca

   See if you can join NCT05835310 on ClinicalTrials.gov

4. A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

   The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Research Site, Houston, Texas

   Locations

   107 in total

   Run by

   AstraZeneca

   See if you can join NCT07430306 on ClinicalTrials.gov

5. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

   The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

   Stage

   Phase 3

   Ages

   16 and older

   Site

   Sl0044 50688, Houston, Texas

   Locations

   242 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT06617325 on ClinicalTrials.gov

6. RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   23 in total

   Run by

   Cabaletta Bio

   See if you can join NCT06121297 on ClinicalTrials.gov

7. A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

   The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with activ…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Prolato Clinical Research Center, Houston, Texas

   Locations

   58 in total

   Run by

   Amgen

   See if you can join NCT06570798 on ClinicalTrials.gov

8. Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

   This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of …

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04751396 on ClinicalTrials.gov

9. Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

   The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the dis…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   2 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06434363 on ClinicalTrials.gov